- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03183531
New Protocol for Febrile Neonate Management
New Protocol for Identification of Serious Bacterial Infection in Febrile Newborn
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a prospective observational cohort study, conducted between January 2011 and December 2015 (5 years) at Sisli Hamidiye Etfal Hospital, a tertiary care university-affiliated medical center in Istanbul. Written informed consent was obtained from the parents of all infants enrolled in the study before inclusion. The study protocol was approved by the local ethic committee.
Study population All neonates who were admitted to the neonatal intensive care unit with a rectal temperature of ≥38°C (documented at the time of medical evaluation) were eligible for the participation in this study. The exclusion criteria were gestational age less than 35 weeks, who refused to participate in the study, chromosome abnormality (e.g., trisomy 21, 18), the presence of a chronic disease, congenital malformations (cyanotic heart disease, meningomyelocele), admission to pediatric surgery, started on antibiotics before admission, and incomplete records. A complete history was obtained from the parents of infants, and a specialist in neonatology carried out a physical examination for localizing the source of the fever in all infants.
Data collection The data obtained for all infants included: demographic information (age at admission, gender, and birth weight), general assessment (well or sick-appearing), medical history, physical examination findings, laboratory test results, and final diagnosis. Laboratory investigations including complete blood count, CRP level, blood chemistry and culture, urine sample analysis and culture (obtained by bladder catheterization), and cerebrospinal fluid sample analysis and culture, were carried out. In the presence of respiratory symptoms or signs, chest radiography was performed. Lumbar puncture was performed according to the ward's policy, which is required for every infant if neurologic findings are positive or without the focus on fever. Stool specimens were obtained when a history of diarrhea was noted and sent for white blood cell analysis and bacterial culture. Other tests were conducted as necessary. Skin, soft tissue, and ear infections were diagnosed by physical examination.
Definition of SBI An episode of SBI was defined as (A) the growth of a known pathogenic bacteria in one or more of cultures (bacteremia, meningitis, osteomyelitis, suppurative arthritis, urinary tract infection, bacterial enteritis, and pneumonia), (B) any disease commonly associated with bacterial pathogens including pneumonia, acute otitis media, suppurative arthritis, osteomyelitis, and soft-tissue infections (cellulitis, abscess, mastitis, and omphalitis). Pneumonia was defined as a new discrete infiltration on the chest film, which was confirmed by an attending pediatric radiologist with the presence of typical clinical signs and symptoms.
All specimens for culture were evaluated by standard microbiological methods. No specimens were processed for viral cultures. The blood culture isolates were considered pathogenic if the organism was known to cause disease in healthy infants. UTI (urinary tract infection) was defined as the isolation of >104 CFU/mL of urine of a single pathogen by catheterization. A positive urine analysis was defined by a positive test for leucocyte esterase or nitrite by the dipstick method or leukocyte ≥10 cells/mm3 in uncentrifuged urine. Methods of viral agent evaluation: in infants with viral respiratory symptoms and complaints (a runny nose, sneezing, coughing), the presence of RSV-Ag (rapid immunochromatographic test produced by Prima lab SA, Switzerland), and influenza-Ag (Immunoassay test produced by Dalian Rongbang Medical Healthy Devices, Spain) were assessed from nasopharyngeal secretions. The body weight of the subjects was taken on admission and weight loss was assessed according to the birth weight. The proportion of weight loss more than twelve percent of birth weight was considered as dehydration.
All patients were hospitalized and prophylactic antibiotic therapy was started and continued for at least 72 hours (cases diagnosed only with dehydration did not receive antibiotics).
Newly proposed protocol (Sisli Etfal) includes:
(1) Unremarkable medical history (no perinatal antibiotics, no underlying disease, not hospitalized longer than the mother), (2) Good appearance, (3) No focal physical signs of infection, (4) CRP level < 1 mg/dl, (5) WBC 5000-15000 counts/mm3 and band/neutrophil ratio (I/T) <0.2, (6) A normal urine analysis.
The infants with all these criteria were considered to have a low risk for SBI. All infants were classified at low-risk by the criteria of Rochester, Boston, Philadelphia and Sisli Etfal protocols. The criteria of four protocols are presented in Table 1.
Statistical analysis The data were analyzed by using SPSS version 15.0 (SPSS, Chicago, IL, USA). Categorical variables are reported as percentages, and normally distributed data are expressed as mean±SD. Statistical comparisons between two groups performed with Student's t-test for normally distributed data, Mann-Whitney U test for non-normally distributed data, and chi-square test for all numerical and categorical values. The positive predictive value (PPV) for SBI of at least one abnormal criteria and the NPV for SBI of the low-risk criteria, in combination, were calculated by the standard statistical formula. All patients were evaluated according to the Boston, Philadelphia, Rochester and Sisli Etfal protocols, and the results were compared for sensitivity, specificity, NPV, PPV, and accuracy values. For predicting SBI, the serum levels of CRP and WBC count were subjected to receiver operating characteristics (ROC) curve analysis. The results were considered to be significant if analysis yielded p<0.05.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
İstanbul, Turkey, 34250
- Sisli Etfal Education and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All neonates who were admitted to the neonatal intensive care unit with a rectal temperature of ≥38°C (documented at the time of medical evaluation) were eligible for the participation in this study.
Exclusion Criteria:
- The exclusion criteria were gestational age less than 35 weeks, who refused to participate in the study, chromosome abnormality (e.g., trisomy 21, 18), the presence of a chronic disease, congenital malformations (cyanotic heart disease, meningomyelocele), admission to pediatric surgery, started on antibiotics before admission, and incomplete records.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of characteristics of febrile neonate and describe the incidence of SBI in febrile neonates.
Time Frame: 5 years
|
All febrile neonate admitted and evaluated for SBI.
An episode of SBI was defined as (A) the growth of a known pathogenic bacteria in one or more of cultures (bacteremia, meningitis, osteomyelitis, suppurative arthritis, urinary tract infection, bacterial enteritis, and pneumonia), (B) any disease commonly associated with bacterial pathogens including pneumonia, acute otitis media, suppurative arthritis, osteomyelitis, and soft-tissue infections (cellulitis, abscess, mastitis, and omphalitis).
Pneumonia was defined as a new discrete infiltration on the chest film, which was confirmed by an attending pediatric radiologist with the presence of typical clinical signs and symptoms.
|
5 years
|
Usefulness of major protocols and new protocol in evaluating only febrile neonate.
Time Frame: 5 years
|
All infants were classified at low-risk by the criteria of Rochester, Boston, Philadelphia and new created Sisli Etfal protocols.
|
5 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- sislietfal.06.2017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Newborn; Infection
-
Intermountain Health Care, Inc.Unknown
-
Kahramanmaras Sutcu Imam UniversityAydin Adnan Menderes UniversityCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Johns Hopkins Bloomberg School of Public HealthEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedMaternal Infection Affecting NewbornBangladesh
-
Beijing Children's HospitalShandong UniversityRecruitingPharmacokinetics | Infection | Newborn | FluconazoleChina
-
Hisar Intercontinental HospitalCompletedCircumcision | Newborn; Infection | DisinfectionTurkey
-
Centre Hospitalier Universitaire, AmiensUnknown
-
Centre de Recherche Médicale de LambarénéUniversity Hospital TuebingenUnknownMaternal Infection Affecting Newborn
-
Tufts Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingInfection; NewbornUnited States
-
Hamilton Health Sciences CorporationCompletedInfection | Sepsis NewbornCanada
Clinical Trials on C reactive protein
-
Henning BliddalCompleted
-
Central Hospital, Nancy, FranceCompletedCrohn DiseaseFrance
-
Corporacion Parc TauliUnknown
-
Moroccan Society of SurgeryRecruitingAnastomotic Leak | Digestive System Neoplasm | C-Reactive ProteinMorocco
-
University of MonastirCompleted
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedLeukemia | Cancer | Stem Cell TransplantationUnited States
-
Zagazig UniversityCompleted
-
Centre Hospitalier Departemental VendeeCompletedColorectal Postoperative ComplicationFrance
-
Sohag UniversityNot yet recruiting
-
Centre Hospitalier Universitaire DijonCompletedInfectious Complications After Colorectal SurgeryFrance